---
title: Cell Therapies vs SCTbio
slug_a: celltherapies
slug_b: sctbio
site: cdmo
review_signal_gate: closed
canonical_path: /compare/celltherapies/sctbio
generated_by: BioBM Editorial AI
---

# Cell Therapies vs SCTbio

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Cell Therapies (celltherapies) is listed for cdmo. GMP contract manufacturer of autologous and allogeneic cell therapies from first-in-human trials through commercial supply, with two decades of experience in CAR-T, mesenchymal stromal cells, TILs, and pluripotent stem cell derivatives. Offers end-to-end cold chain management, process development, quality control analytics, and regulatory consulting across Australia and Asia-Pacific.

Services: 9. Modalities: 2. Indications: 1. Locations: 1. Certifications: 4. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (9).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

SCTbio (sctbio) is listed for cdmo. SCTbio is a European cell and gene therapy CDMO offering cGMP manufacturing, lentiviral and gammaretroviral vector production, analytical development, and QP batch release. Its facilities include 420 m² of Class A/B/C GMP cleanrooms, and it reports more than 2,000 GMP batches manufactured.

Services: 10. Modalities: 2. Indications: 1. Locations: 2. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (10).

Review summary: Review summary withheld until site-level review gate opens.